Chicago Equity Partners LLC trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ) by 5.2% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 504,921 shares of the company’s stock after selling 27,795 shares during the quarter. Johnson & Johnson makes up about 1.8% of Chicago Equity Partners LLC’s portfolio, making the stock its 3rd largest holding. Chicago Equity Partners LLC’s holdings in Johnson & Johnson were worth $66,796,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds also recently added to or reduced their stakes in the stock. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its holdings in Johnson & Johnson by 29.9% during the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after acquiring an additional 200 shares during the last quarter. Lenox Wealth Advisors Inc. grew its holdings in Johnson & Johnson by 0.6% during the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock worth $116,000 after acquiring an additional 5 shares during the last quarter. Shine Investment Advisory Services Inc. bought a new stake in Johnson & Johnson during the 2nd quarter worth approximately $177,000. Ullmann Financial Group Inc. bought a new stake in Johnson & Johnson during the 1st quarter worth approximately $186,000. Finally, Puplava Financial Services Inc. bought a new stake in Johnson & Johnson during the 2nd quarter worth approximately $202,000. Institutional investors and hedge funds own 65.90% of the company’s stock.
A number of research firms have weighed in on JNJ. Vetr raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 target price on the stock in a report on Monday, October 30th. Citigroup boosted their target price on shares of Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a report on Monday, October 23rd. Credit Suisse Group set a $154.00 target price on shares of Johnson & Johnson and gave the stock an “outperform” rating in a report on Thursday, October 19th. Jefferies Group boosted their target price on shares of Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a report on Monday, October 16th. Finally, Barclays boosted their target price on shares of Johnson & Johnson from $140.00 to $148.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 18th. Four investment analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $144.59.
Johnson & Johnson (JNJ) traded up $1.40 during trading hours on Wednesday, hitting $141.07. 1,120,404 shares of the stock were exchanged, compared to its average volume of 5,877,685. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $144.35. The company has a market cap of $373,453.13, a price-to-earnings ratio of 19.47, a P/E/G ratio of 2.83 and a beta of 0.80.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, beating the Zacks’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The company had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. During the same period in the prior year, the firm posted $1.68 EPS. The company’s quarterly revenue was up 10.3% on a year-over-year basis. equities analysts expect that Johnson & Johnson will post 7.28 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 2.38%. The ex-dividend date of this dividend is Monday, November 27th. Johnson & Johnson’s dividend payout ratio is presently 58.33%.
COPYRIGHT VIOLATION NOTICE: This story was first published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://ledgergazette.com/2017/12/06/chicago-equity-partners-llc-sells-27795-shares-of-johnson-johnson-jnj.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.